Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)
Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug
Gossamer Bio said last month it had paused a Phase Ib/II study of its BTK inhibitor due to “benefit/risk profile.” Now, the biotech revealed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
